Header cover image

Singaporean (SGX) Pharma Industry Analysis

UpdatedFeb 20, 2024
DataAggregated Company Financials
  • 7D1.5%
  • 3M-2.2%
  • 1Y-13.4%
  • YTDn/a

Over the last 7 days, the Pharma industry has remained flat, although notably iX Biopharma declined by 4.8%. As for the longer term, the industry has declined 14% in the last year. Looking forward, earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the Singaporean Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 20 Feb 2024S$2.3bS$371.2mS$172.1m12.5x13.1x6.1x
Thu, 18 Jan 2024S$2.3bS$371.1mS$172.1m12.6x13.1x6.1x
Sat, 16 Dec 2023S$2.2bS$371.1mS$172.1m12.4x12.9x6x
Mon, 13 Nov 2023S$5.0bS$1.5bS$308.0m12.4x16.3x3.3x
Wed, 11 Oct 2023S$5.3bS$1.5bS$326.9m9.9x16.3x3.5x
Fri, 08 Sep 2023S$5.3bS$1.5bS$326.3m10.4x16.3x3.5x
Sun, 06 Aug 2023S$5.8bS$1.5bS$289.8m10.6x19.9x3.8x
Tue, 04 Jul 2023S$6.0bS$1.5bS$288.2m10.5x20.8x3.9x
Thu, 01 Jun 2023S$7.1bS$1.6bS$291.2m11.2x24.3x4.6x
Sat, 29 Apr 2023S$6.3bS$1.6bS$268.0m13.5x23.3x4x
Mon, 27 Mar 2023S$5.3bS$1.4bS$265.1m8.8x20.2x3.8x
Wed, 22 Feb 2023S$5.9bS$1.4bS$251.8m9.6x23.3x4.3x
Fri, 20 Jan 2023S$5.1bS$1.4bS$264.5m8.7x19.5x3.7x
Sun, 18 Dec 2022S$4.9bS$1.4bS$261.2m8.2x18.7x3.6x
Tue, 15 Nov 2022S$5.0bS$1.3bS$255.8m10.8x19.4x3.7x
Thu, 13 Oct 2022S$4.3bS$1.3bS$246.3m10.1x17.5x3.3x
Sat, 10 Sep 2022S$4.8bS$1.3bS$249.6m10.8x19.4x3.6x
Mon, 08 Aug 2022S$4.8bS$1.3bS$228.3m10.1x20.9x3.6x
Wed, 06 Jul 2022S$5.0bS$1.3bS$229.3m10.2x21.8x3.7x
Fri, 03 Jun 2022S$4.8bS$1.3bS$228.7m10.8x21.1x3.6x
Sun, 01 May 2022S$14.1bS$1.3bS$231.8m12.4x60.6x10.5x
Tue, 29 Mar 2022S$5.4bS$1.4bS$248.4m12x21.9x3.9x
Thu, 24 Feb 2022S$5.5bS$1.4bS$220.0m14.4x24.8x4x
Sat, 22 Jan 2022S$5.7bS$1.3bS$212.9m14.6x26.9x4.3x
Mon, 20 Dec 2021S$5.3bS$1.3bS$212.2m14.1x25x4x
Wed, 17 Nov 2021S$5.4bS$1.3bS$211.9m14.5x25.4x4x
Fri, 15 Oct 2021S$5.4bS$1.3bS$203.8m14.3x26.6x4.1x
Sun, 12 Sep 2021S$5.7bS$1.3bS$203.2m22.4x28.2x4.4x
Tue, 10 Aug 2021S$6.0bS$1.3bS$203.2m22.3x29.7x4.6x
Mon, 03 May 2021S$5.5bS$1.3bS$205.8m21.6x26.8x4.3x
Price to Earnings Ratio


Total Market Cap: S$4.6bTotal Earnings: S$218.6mTotal Revenue: S$1.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Singaporean Pharma Industry Price to Earnings3Y Average 21.7x202220232024
Current Industry PE
  • Investors are pessimistic on the Singaporean Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.0x which is lower than its 3-year average PE of 21.8x.
  • The 3-year average PS ratio of 4.0x is lower than the industry's current PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 7.7% per year over the last three years,
  • Revenues have also declined 33% per year.
  • This means overall sales from these companies are declining and profits are subsequently falling as well.

Industry Comparison

How does Singaporean Pharma compare with similar industries?

SG Market2.32%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
H02 Haw ParS$9.702.2%
42C iX BiopharmaS$0.0432.4%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News



Haw Par







iX Biopharma